Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of FH-006 for injection in advanced malignant solid tumors
CTR20253286Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2025
- Countries
- 1
01
Overview
A Phase 2 trial of FH-006 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Sep 2025; status: active.
02
Drugs
FH-006
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253286.